asThe full implementation of the 'Artificial Intelligence+' initiative and the '15th Five-Year Plan' have listed biomedicine as a new pillar industry. The intelligent transformation driven by AI is undergoing a profound leap from single-point technological breakthroughs to collaborative innovation across the entire industrial chain. Currently, AI technology has been fully integrated into core scenarios such as drug research and development, clinical research, and commercialization. Driven by the continuous activity of investment and financing in the primary market and the record-breaking scale of BD transactions among multinational pharmaceutical companies, AI-driven drug manufacturing has become the underlying infrastructure for reshaping the core competitiveness of the pharmaceutical industry.
Although the industry still faces systemic challenges in data governance, algorithm explainability, and clinical validation pathways, the combined efforts of policies and capital are accelerating the closure of the industrial loop. Against this backdrop, how to graspThe '15th Five-Year Plan' strategic opportunity has become the core issue for all participants in the industrial chain to achieve differentiated competitive advantages and sustainable development.
Based onWith the continuous research and accumulation of AI technology in healthcare and cutting-edge technology fields, Frost & Sullivan (Frost &Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') plans to officially release the 'Global AI Pharmaceutical Industry Development Blue Book 2026' in July 2026 and sincerely invites companies in the industry to participate to promote industry development.
Research content
This time,The 'Global AI Pharmaceutical Industry Development Blue Book 2026' will systematically define the technical and application scopes of the global AI pharmaceutical industry, deeply dissect the reconstruction logic of its traditional drug R&D paradigm, and based on the analysis of the upstream and downstream collaborative ecosystem of the industrial chain, combined with the active investment and financing in the primary market and the trend of licensing transactions, it will delve into the core factors driving industrial transformation and future evolution directions.
Centering on various drug R&D, this blue book will conduct a systematic analysisThe technical principles and application scenarios of AI in multimodal drug development cover small molecule targeted drugs, peptide drugs, antibody drugs, nucleic acid drugs, and cell gene therapy. In response to the technical challenges and unmet clinical needs of different modal drugs, the Blue Book will delve into how AI helps to break through key R&D bottlenecks, provide a new path from targets to molecules for drug innovation, and open up new directions for technological breakthroughs for enterprises.
During the clinical research phase, the Blue Book will conduct a comprehensive reviewThe multiple key dimensions empowered by AI include the design and optimization of clinical trial protocols, patient stratification and precision enrichment, patient recruitment and intelligent matching, adaptive trial design and dynamic adjustment, analysis of patient subtypes and individualized benefit assessment, automated data collection and intelligent monitoring, as well as the integration of real-world evidence and post-marketing pharmacovigilance. Through these systematic analyses, the Blue Book will demonstrate how AI can penetrate the entire clinical research process, significantly improving trial efficiency and success rates, helping enterprises shorten R&D cycles and reduce investment risks.
In the commercialization segment, the Blue Book will provide an in-depth interpretation.How AI drives the precise realization of commercial value after product launch, covering core scenarios such as differentiated competitive positioning and medical evidence production, simulation of medical insurance negotiation access and optimization of pricing strategies, digital-driven precision medicine communication and full-channel value management, smart supply chain and refined demand forecasting. The Blue Book will demonstrate how AI assists enterprises in optimizing market access decisions and improving business operational efficiency, providing data-driven strategic support for value transformation after product launch.
At the level of organ-on-a-chip technology, the Blue Book will also focus on its empowering pathways in high-fidelity preclinical safety evaluation, automated high-throughput phenotyping screening, discovery of new targets and research on pharmacodynamic mechanisms, as well as supporting the evolution of regulatory paradigms. By systematically presenting organ-on-a-chip technology andThe collaborative innovation of AI, as outlined in the Blue Book, will clarify how AI can improve the predictive accuracy and screening throughput of organ-on-a-chip models. This will assist in drug development by obtaining more physiologically relevant validation data, thereby reducing the risk of clinical translation.
Relying on the collaborative innovation perspective of the entire industrial chain, this blue book aims to mapThe comprehensive blueprint for AI-powered intelligent transformation of the pharmaceutical industry, helping the industry achieve a profound transformation from technological breakthroughs to value leaps. At the same time, the report will feature an enterprise special section, systematically presenting the development history, product pipeline layout, and core technical capabilities of representative enterprises. Under the overall industry framework, it will display the positioning and competitive advantages of enterprises in the industrial chain. Combining dimensions such as iterative underlying algorithm models, clinical validation pathways, and standard system construction, a comprehensive judgment on the trend of breaking through industry bottlenecks and paradigmatic transformation will be formed.
Frost & Sullivan will collaborate with multiple stakeholders within the industry chain to participate in the research and release process. Under a professional research framework, they will form a rational expression of industry development and accumulate consensus, jointly promoting ChinaThe long-term and healthy development of the AI pharmaceutical industry.
Release Highlights
1.Increase the propagation potential
The Blue Book, as a systematic industry research output, is made available to the public through the Frost & Sullivan official website, Frost & Sullivan's global media matrix, andAI and healthcare vertical media channels are published, and the content is widely disseminated on mainstream financial platforms. The Blue Book systematically presents the core strengths of enterprises in terms of technology layout, product capabilities, and industrial collaboration, enhancing market recognition and trust in the professionalism of enterprises, improving industry influence and brand awareness, and providing a window for cooperative enterprises to voice their opinions and focus on targeted communication with authoritative voices.
The English version will also be made available simultaneously on globally renowned news agencies (such as The Associated Press), mainstream financial media (such as Yahoo Finance), top North American financial media and websites (Business Insider, Dow Jones Market Watch,Benzinga, Wall Street Insider, and other top media outlets from various regions around the world. Further expand the brand voice and influence of the enterprise in the international market, effectively helping Chinese AI pharmaceutical companies advance global brand building and product layout.
2.Establish ecological connectivity
Through the Blue Book Research and Publication Platform, we promote in-depth exchanges and cooperation docking among enterprises within the context of the industrial chain.
Under the industry development framework, it demonstrates the enterprise's positioning and competitive advantages within the industrial chain, strengthens cognitive connections with upstream and downstream enterprises, partners, and relevant institutions, promotes technological collaboration and resource integration, and creates a foundation for subsequent cooperation.
3.Establish industry image
The Blue Book will objectively present the business situation and industry status of enterprises from dimensions such as industry development stages, competitive landscape, and trend analysis.
By systematically presenting research content, the enterprise strengthensThe professional image and strategic positioning in the field of AI pharmaceuticals enhance recognition and influence within the industry and external markets.
4.Overwrite capital market concerns
Relying on Frost & Sullivan's network of partners and followers in primary and secondary markets, the release of research findings helps to enhance a company's visibility and attention in the capital market.
By disseminating research findings, we aim to attract the attention of potential investors and related institutions and promote effective communication with the capital market.
5.Lay the foundation for long-term cooperation
The in-depth exchanges formed through the Blue Book cooperation help both parties further explore potential cooperation in brand communication, investment and financing consulting, growth strategies, etc., laying a foundation for long-term follow-up cooperation.
